The QualityStocks Daily Wednesday, June 13th, 2018

Today's Top 3 Investment Newsletters

CannabisNewsWire (CHOOF) +39.00%

StreetInsider (PVTL) +32.96%

BUYINS.NET (ENPH) +32.89%

The QualityStocks Daily Stock List

Royale Energy, Inc. (ROYL)

SmallCapVoice, Marketbeat, Wall Street Resources, Investing Futures, WealthMakers, Turn Key Oil, Stock Analyzer, Microcapmillionaires, Jason Bond, SmarTrend Newsletters, and Oakshire Financial reported earlier on Royale Energy, Inc. (ROYL), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Royale Energy, Inc. concentrates on the acquisition, development, and marketing of natural gas and oil. It owns and operates wells in the Sacramento and San Joaquin basins in California and has royalty interests in Alaska. The Company engages in the production and sale of natural gas; the acquisition of oil and gas lease interests and proved reserves; the drilling of exploratory and development wells; and the sale of fractional working interests in wells to undergo drilling. Royale Energy has its corporate office in El Cajon, California.

Royale Energy has properties encompassing more than 20,000 acres in California and nine 3D seismic surveys in the Sacramento Basin. Currently, the Company operates greater than 60 natural gas wells. It owns interests in 12 natural gas fields in California.

Royale Energy’s North Arbuckle is in Colusa County in the Sacramento Basin. At present, this is the most active area for the Company. It has 10 producing natural gas wells that have produced over 5 billion cubic ft.

Royale has acquired greater than 96,000 acres on the Alaskan North Slope. The acreage spans over 88 miles east and west of the Trans-Alaska pipeline route.

The Company has its Lonestar Field. It includes in excess of 1,000 acres. The Lonestar Field has produced more than five billion cubic ft. of gas from five separate Forbes sandstone reservoirs. The Lonestar Field includes the Goddard 7-1 Well; the Goddard #2 and Goddard #3 (offset wells to the Goddard 7-1); and the Magnum Well.

Additionally, Royale’s Victor Ranch Field is in Tehama County, in the Northern Sacramento Basin. This field has been producing natural gas for the Company since it drilled its first well there in 1993.

Royale Energy has an agreement with a major independent exploration and development company to expand its joint development agreement in the Sacramento Basin of Northern California. The expanded arrangement covers about 1,900 acres in the Rio Vista Gas Field. Royale will target the Capay and Martinez sands.

Royale Energy and Matrix Oil Management Corporation jointly announced earlier in 2018 the closing and completion of the merger between Royale and Matrix. The merger transaction was approved by the Matrix and Royale Energy shareholders on November 16, 2017. It closed after the companies received the consent of Matrix’s lender, Arena Limited SPV, LLC.

Royale Energy and CIC Partners have created a new Joint Venture (JV) named RMX Resources. This JV will fund, drill and produce oil at the prolific Sansinena Oil Field. CIC contributed an aggregate of $25,000,000 in cash in exchange for an 80 percent equity interest. Royale Energy received a 20 percent equity interest plus working capital in exchange for contribution of Sansinena and surrounding area assets. CIC is a Dallas-based private equity organization.

Last month, Royale Energy announced the appointment of Board Director Mr. Rod Eson as Chief Executive Officer (CEO) effective (immediately). Before accepting the CEO responsibilities at Royale Energy, Mr. Eson served as the CEO of Foothill Energy LLC, a California-focused company he founded in 2004.

Royale Energy, Inc. (ROYL), closed Wednesday's trading session at $0.381, up 0.26%, on 1,260 volume with 3 trades. The average volume for the last 60 days is 14,705 and the stock's 52-week low/high is $0.316/$0.50.

chart

Cotinga Pharmaceuticals, Inc. (COTQF)

NetworkNewsWire, Stockhouse, InvestorsHub, MarketWatch, YCharts, and Penny Stock Hub reported on Cotinga Pharmaceuticals, Inc. (COTQF), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Cotinga Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer. The Company uses proprietary artificial intelligence (AI) technologies to pursue a targeted and transformational approach to treating cancer and other unmet medical needs. Cotinga’s drug candidates have demonstrated the ability to target key pathways and prevent cancer cells from thriving and replicating.

Cotinga Pharmaceuticals has offices in Boston, Massachusetts and London, Ontario. The Company formerly went by the name Critical Outcome Technologies, Inc. It changed its corporate name to Cotinga Pharmaceuticals, Inc. in January 2018.

The intention of the Company’s CHEMSAS® technology is to expedite the discovery and development of novel drug therapies, allowing Cotinga to build a pipeline of potential drug candidates faster and with a higher probability of success than traditional methods.

CHEMSAS® is a multi-staged computational platform technology. It is established upon a hybrid of machine learning technologies and proprietary algorithms that allows prediction of biological activity from molecular structures.

Cotinga Pharmaceuticals’ lead compound is COTI‐2. It has a novel p53‐dependent mechanism of action with selective and potent anti-cancer activity.

COTI‐2 is initially undergoing evaluation for the treatment of gynecologic cancers and head and neck squamous cell carcinoma in a Phase 1 clinical trial at the MD Anderson Cancer Center at the University of Texas and the Lurie Cancer Center at Northwestern University. Cotinga Pharmaceuticals has secured orphan drug status in the United States for COTI‐2 for the treatment of ovarian cancer.

The Company’s second lead compound is COTI-219. This is a novel oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS function.  KRAS mutations occur in up to 30 percent of all cancers.

COTI-219 is undergoing IND-enabling studies to support a regulatory submission. COTI-2 and COTI-219 are the first compounds derived with the benefit of CHEMSAS® to be developed by Cotinga Pharmaceuticals.

The continuing Phase 1 trial of COTI-2 is currently evaluating COTI-2 as a monotherapy for the potential treatment of gynecological malignancies and HNSCC. Cotinga Pharmaceuticals announced last year top-line data from the gynecological malignancies arm of the trial demonstrating COTI-2 was generally safe and well-tolerated. COTI-2 also exhibited an encouraging pharmacokinetic/pharmacodynamic profile and signals of efficacy.

Cotinga’s technology also includes ROSALIND™. This is a simulation platform designed to provide better personalized treatment options based on the genetic profile of the patient’s cancer.

Last month, Cotinga Pharmaceuticals announced the clearance of a protocol amendment for its ongoing clinical trial of COTI-2. The multi-part protocol amendment expands the trial to evaluate COTI-2 as a combination therapy in a broad array of cancers. Cotinga will initially evaluate COTI-2 combined with standard of care cisplatin in up to 30 patients with any of ovarian, fallopian tube, primary peritoneal, endometrial, cervical, lung, pancreatic or colorectal cancer, or head and neck squamous cell carcinoma.

Cotinga Pharmaceuticals, Inc. (COTQF), closed Wednesday's trading session at $1.40, even for the day. The average volume for the last 60 days is 4,899 and the stock's 52-week low/high is $0.10/$2.498.

chart

Esports Entertainment Group, Inc. (GMBL)

RedChip, Real Pennies, OTC Markets, and Proactive Investors reported previously on Esports Entertainment Group, Inc. (GMBL), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Esports Entertainment Group, Inc. is a next generation, licensed, online gambling business particularly focused on esports wagering. The Company’s plan is to offer wagering on esports events in a fully licensed, regulated, and secured platform to the international esports audience, excluding the United States. Esports Entertainment Group has its offices in St. Mary's, Antigua, and Barbuda.

The Company is a licensed online gambling enterprise with a specific emphasis on esports wagering and 18+ gaming. A team of industry and technical experts from the online gambling and video game industries, and esports, marketing, legal, and financial professionals lead Esports Entertainment Group.

The Company’s online esports gambling platform will be completely licensed and the highest regulated esports gambling site in the world. Esports Entertainment’s intention is to offer users globally the ability to participate in multi-player video games tournaments online for cash prizes. Currently, the Company is developing a number of play money websites and its real money wagering website.

Esports Entertainment Group has been issued a Client Provider Authorization Permit by the Kahnawake Gaming Commission. The Company has applied for an Interactive Wagering License with the Financial Services Regulatory Commission of Antigua and Barbuda to conduct real money interactive gaming on a worldwide basis from centers in Canada and Antigua.

Recently, Esports Entertainment Group announced the signing of Affiliate Marketing Agreements with 14 additional esports teams as it builds affiliate marketing activities in support of its recent launch of VIE (https://vie.gg), an esports wagering platform. The addition of these 14 esports teams brings the total number of esports team affiliates to 50 since Esports Entertainment’s first announcement on April 5, 2018.

VIE offers bet exchange style wagering on esports events in a licensed, regulated and secured platform to the global esports audience. This excludes jurisdictions such as the U.S. that prohibit online gambling. The bet exchange model provides for player versus player betting (PVP). The house takes a small percentage of each wager.

Esports Entertainment also recently announced an agreement with PartnerMatrix. This is the first platform that enables online sportsbook and casino operators to run Affiliate System with Agent functionality and Agent System with Affiliate functionality. With this agreement, Esports Entertainment will integrate the PartnerMatrix platform to manage its affiliate program on an accelerated basis.

Esports Entertainment Group, Inc. (GMBL), closed Wednesday's trading session at $0.8001, down 10.10%, on 8,709 volume with 7 trades. The average volume for the last 60 days is 39,535 and the stock's 52-week low/high is $0.147/$3.14.

chart

Lixte Biotechnology Holdings, Inc. (LIXT)

Real Pennies, Stockhouse, 4-Traders, MarketWatch, InvestorsHub, and Simply Wall St reported on Lixte Biotechnology Holdings, Inc. (LIXT), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Lixte Biotechnology Holdings, Inc. is a drug discovery company listed on the OTC Markets Group’s OTCQB. It uses biomarker technology to identify enzyme targets associated with serious common diseases and subsequently designs novel compounds to attack those targets.

Lixte’s product pipeline covers two major categories of compounds at different stages of pre-clinical and clinical development that it believes have wide-ranging therapeutic potential for cancer and other debilitating and life-threatening diseases. A clinical-stage company, Lixte Biotechnology has its corporate office in East Setauket, New York.

Lixte’s cancer drug development strategy has led to the discovery of novel compounds. The phosphatase inhibitors are in pre-clinical development for reducing the extent of tissue damage following stroke, heart attack, and septic shock. The deacetylase inhibitors are in pre-clinical development for the prevention and treatment of neurodegenerative diseases, traumatic brain injury, and topically for fungal dermatitis.

The Company’s dedication is to discovering drugs for more effective treatments for cancer. It has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models.

Lixte Biotechnology’s current drug portfolio includes inhibitors of serine/threonine protein phosphatases, which are vital to cell division. Its portfolio also includes DNA damage repair and inhibitors of protein deacetylases that regulate pathways of gene expression and protein degradation.

Lixte Biotechnology’s innovative phosphatase inhibitor is LB-100, its lead compound. LB-100 is in a Phase I clinical trial at two NCI designated Comprehensive Cancer Centers and three U.S. Oncology Research locations.

The Company granted an exclusive license of its LB-100 for the treatment of hepatocellular carcinoma (HCC) in Asia to Taipei Medical University (TMU). LB-100 is not presently approved for treatment of HCC.

Lixte Biotechnology’s strategy is to attack novel enzyme targets. This strategy has led to the discovery that its phosphatase inhibitors may be therapeutically useful not only in cancer but for treatment of important non-neoplastic diseases. This includes stroke and heart attack, vascular complications of type 2 diabetes, as well as severe depression.

Lixte Biotechnology Holdings, Inc. (LIXT), closed Wednesday's trading session at $0.19, even for the day, on 1,000 volume with 1 trade. The average volume for the last 60 days is 2,985 and the stock's 52-week low/high is $0.094/$0.25.

chart

MYnd Analytics, Inc. (MYND)

Simply Wall St, 4-Traders, Barchart, OTC Markets, The Street, Business Insider, Bzweekly, Stock Twits, Zacks, Equity Clock, Capital Cube, BioSpace, MarketWatch, GuruFocus, and Marketbeat reported on MYnd Analytics, Inc. (MYND), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

MYnd Analytics, Inc. is a market leader in decreasing costs and improving the delivery of mental health services through the combination of telemedicine and data analytics/artificial (augmented) intelligence. A predictive medicine company, MYnd brings objective physical findings to psychiatric treatment to reduce trial and error treatment in mental health. The Company provides an innovative set of reference data and analytic tools for clinicians and researchers in psychiatry. MYnd Analytics is based in Mission Viejo, California.

The Company has its Psychiatric EEG Evaluation Registry, or PEER Online®. The aim of PEER Online is to provide objective, personalized data to assist physicians in the selection of appropriate medications. PEER Online is a cloud-based platform. It is a registry and reporting platform. It enables medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained by way of a standard electroencephalogram (EEG).

PEER combines a "crowdsourced" secure physician outcome registry with electroencephalogram (EEG), an accepted, well-normed test of brain function. EEG is a totally painless, non-invasive test. It records one’s brain’s electrical activity.

MYnd Analytics has its MYnd Analytics Center. This Center provides a convenient, relaxing, and welcoming environment for one to receive their EEG and PEER Report™. The EEG is performed on-site at the MYnd Analytics Center. It generally takes under one hour. The EEG and PEER Report are available by appointment only. Physicians who use PEER reduce trial and error prescribing.

MYnd Analytics announced in February of this year that it received its first notice of patent allowance in Canada on its neuromodulation platform for predicting patients likely to respond to Transcranial Magnetic Stimulation (TMS). The patent is entitled “Method for Assessing the Susceptibility of a Human Individual Suffering from a Psychiatric or Neurological Disorder to Neuromodulation Treatment.” It provides patent protection through 2029. 

MYnd Analytics continues to integrate its recently acquired Arcadian Telepsychiatry Services LLC business into its legacy business. Recently, MYnd Analytics announced that its wholly-owned subsidiary, Arcadian Telepsychiatry Services launched a new program to offer, via its network of Providers, youths in rural, suburban and urban markets with school-based access to telepsychiatry, teletherapy and other mental health services.

Telepsychiatry involves the use of video conferencing equipment to conduct real time mental health consultations between a clinician and a patient. The design of this program is to benefit children and teenagers throughout the nation, particularly those with limited access to mental health services.

MYnd Analytics, Inc. (MYND), closed Wednesday's trading session at $2.17, down 3.12%, on 51,725 volume with 209 trades. The average volume for the last 60 days is 281,165 and the stock's 52-week low/high is $1.149/$6.98.

chart

AEON Global Health Corp. (AGHC)

Amigo Bulls, Stockopedia, Penny Stock Hub, Stockwatch, Simply Wall St, Zacks, Stockflare, Dividend Investor, Stockhouse, InvestorsHub, YCharts, TradingView, The Street, Stock Target Advisor, and Investors Hangout reported on AEON Global Health Corp. (AGHC), and today we report on the Company, here at the QualityStocks Daily Newsletter.

AEON Global Health Corp., together with its subsidiaries, provides a variety of clinical laboratory testing services in the United States. The Company offers diagnostic services in Cancer Genomics, Toxicology, Pharmacogenomics, and Health Technology Applications. The Company formerly went by the name Authentidate Holding Corp. It changed its name to AEON Global Health Corp. in January 2018. AEON Global Health is headquartered in Gainesville, Georgia.

AEON is the fastest growing clinical lab and healthcare services organization in the U.S. It is first in healthcare technology research and development (R&D) where its proprietary methodologies provide expedited and highly accurate urine and oral fluid (saliva) test results.

Essentially, AEON Global Health’s primary business focus is providing a “personalized medicine” approach to laboratory testing services. This is to provide customers with actionable medical information.

AEON is an innovator in the genomic testing area. The Company has an extensive menu of genetic tests and a pipeline of additional molecular-based tests in development. AEON Global Health provides post contract customer support services.

AEON Clinical Labs services include Cancer Genomics, Pharmacogenomics, Toxicology, and Women’s Health. Health Technologies services include Inscrybe®. This is a secure and simple interface. Inscrybe® allows physicians, nurses, hospital staff, and external care facilities or health insurers to send, receive, sign, and track healthcare records, supporting documents, patient discharge orders and referrals or lab results and images on the web or via electronic fax instead of transferring paper.

The design of AEON’s Telehealth Solutions is to improve outcomes and reduce hospital readmission through helping clinicians closely monitor patients with chronic illnesses such as CHF, COPD and Diabetes.

AEON Global Health has agreed with Sabal Therapeutics, LLC to be the principal laboratory marketer of Naprosyn®, the branded naproxen oral suspension USP. Under the agreement, AEON Global Health will become the exclusive clinical laboratory marketing representative of Sabal Therapeutics. It will market the drug alongside of its industry-leading drug monitoring service.

Last month, AEON Global Health announced that it earned The Joint Commission's Gold Seal of Approval® for Laboratory Services Accreditation by demonstrating continuous compliance with its performance standards. The Gold Seal of Approval is a symbol of quality, which reflects an organization's commitment to providing safe and effective patient care.

Sonny Roshan, Founder, Chairman and Chief Executive Officer of Aeon Global Health, said, "We are proud that the Joint Commission has provided our laboratory with this prestigious certification. This award reflects our unwavering commitment to maintaining the highest quality of standards in all areas of our operations."

AEON Global Health Corp. (AGHC), closed Wednesday's trading session at $0.63, down 33.68%, on 649 volume with 3 trades. The average volume for the last 60 days is 2,621 and the stock's 52-week low/high is $0.40/$1.75.

chart

Hunter Oil Corp. (HOILF)

Penny Stock Tweets, OTC Markets, Stockwatch, Investor Network, Stockhouse, InvestorsHub, TradingView, CapitalCube, and WalletInvestor reported on Hunter Oil Corp. (HOILF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Hunter Oil Corp., via its subsidiaries, acquires, develops, operates, and exploits crude oil and natural gas properties in the U.S. The Company operates its assets from its operations office in Houston, Texas. Hunter Oil has its head office in Vancouver, British Columbia.

The Company previously went by the name Enhanced Oil Resources, Inc. It changed its name to Hunter Oil Corp. in August of 2016. Its shares trade on the OTCQX.

Hunter Oil owns and operates two large, historic oil fields in the Permian Basin of Eastern New Mexico. These are the Milnesand and Chaveroo fields. Historical production of these two fields is roughly 40 million barrels.

The Milnesand and Chaveroo fields were first developed in the 1950’s and 1960’s with vertical well production technology. This left significant recoverable reserves behind. Hunter Oil has a 100 percent Working Interest (WI) in Milnesand and Chaveroo. In the Permian Basin of New Mexico the Company holds greater than 23,000 gross acres.

Hunter Oil has been preparing its Chaveroo and Milnesand Oil fields for an infield horizontal redevelopment of the San Andres formation, providing Hunter with drill-ready assets. The Company’s preparations include obtaining an agreed compliance order (ACO) with the New Mexico Conservation Division.

Last month, Hunter Oil announced it filed its unaudited interim consolidated financial statements and management's discussion and analysis (MD&A) for the three months ended March 31, 2018. Total Assets were $36.2MM or $2.77 per common share.

Hunter Oil reported $22.9MM in Shareholders' Equity. This represents $1.75 per common share. Net Loss was reduced by 25 percent to $0.7MM versus the same period in 2017. Net Loss per Common Share was $0.08 for the period.

Yesterday, Hunter Oil announced that its wholly-owned subsidiary, Ridgeway Arizona Oil Corp., filed for drilling permits for five wells in its Chaveroo oil field in Roosevelt County, New Mexico. The planned wells will target the San Andres formation at about 4,500’ TVD (true vertical depth) and will be one-mile-long horizontal wells.

Hunter Oil Corp. (HOILF), closed Wednesday's trading session at $1.60, down 20.34%, on 16,634 volume with 19 trades. The average volume for the last 60 days is 3,655 and the stock's 52-week low/high is $0.2533/$2.50.

chart

THC BioMed Intl. Ltd. (THCBF)

YCharts, MarketWatch, and TradingView reported on THC BioMed Intl. Ltd. (THCBF), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

THC BioMed Intl. Ltd. is an authorized licensed producer of dried Marijuana, for Medical Purposes. The OTCQB-listed Company has a production only license for fresh marijuana and cannabis oil. Currently, THC BioMed ships the most live Cannabis plants in Canada. The Company currently offers 29 different genetic strains for sale. THC BioMed is headquartered in Kelowna, British Columbia and it is Canada's largest supplier of legal Cannabis Genetics.

THC BioMed has the largest variety of genetic strains available in Canada for home growers. It has developed strains with a distinct herbal odor. This results in a product that exhibits a less pungent marijuana smell when smoked. The Company is also set to offer royalty-free starting materials to new licensed producers looking to start their business with high-quality genetics.

THC BioMed has its Clone Shipper acquisition. It is laying the groundwork in preparation for becoming the wholesaler of choice of live clones to the expected home growers' market. The patented design of the Clone Shipper 3.0 containers allows for an LED light to keep the clone in the growing vegetative stage for 12 to 24 hours during shipment. THC BioMed is using the newly designed Clone Shipper 3.0 containers to ship live cannabis plants across Canada.

The patent-pending design of the Clone Shipper enables plants, particularly clones or young plants to be shipped safely. This is while nurturing the plant in the growing process. The shipper is built to last for manifold shipments.

In November 2017, THC BioMed announced the creation of THC2GO Dispensaries. THC, by way of its wholly-owned subsidiary "THC2GO Dispensaries", has started the application process to become a cannabis retailer in the Province of Manitoba. In addition, THC2GO Dispensaries’ intention is to apply for retail outlets in each Canadian province that allows private cannabis retail outlets.

Furthermore, this past December, THC BioMed announced that Health Canada amended the Company's ACMPR (Access to Cannabis for Medical Purposes Regulations) license to include four additional Grow Rooms. This will permit THC to ramp up production, adding an additional 400 kilograms per year. The four Grow Rooms went into production on December 15, 2017.

Today, THC BioMed announced that it entered into a Letter of Intent (LOI) to purchase a Farm and Greenhouses in the Niagara region of Ontario. The new property comprises 8 1/2 acres. It has around 7 acres of growing space, including 70,000 square feet of greenhouse space. Irrigation equipment and all equipment and supplies needed for the operation of the greenhouses are included in the purchase price.

THC BioMed Intl. Ltd. (THCBF), closed Wednesday's trading session at $0.8502, up 1.70%, on 24,060 volume with 55 trades. The average volume for the last 60 days is 63,035 and the stock's 52-week low/high is $0.2368/$2.65.

chart

Semler Scientific, Inc. (SMLR)

Money Morning, Wall Street Resources, Marketbeat, and Barchart reported previously on Semler Scientific, Inc. (SMLR), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Semler Scientific, Inc. is a medical risk-assessment Company listed on the OTC Markets’ OTCQB. Its mission is to develop, manufacture, and market patented products, which identify the risk profile of medical patients to permit healthcare providers to capture full reimbursement potential for their services. Semler Scientific provides technology and software solutions to improve the clinical effectiveness of healthcare insurers and physician groups. Semler Scientific is based in Portland, Oregon.

The Company’s diagnostic and testing products and services assist in guiding patient care. They close the gap between the cost of care and compensation for care.

Fundamentally, Semler Scientific provides diagnostic and testing services to the U.S.’s top health plans and providers. The Company’s aim is to develop, manufacture, and market unique proprietary products and services that assist its customers in evaluating and treating chronic diseases.

Semler Scientific manufactures the QuantaFlo™ system for Vascular Disease testing. The QuantaFlo™ system is very suitable for use in primary care offices, specialty practices, health fairs, or during home assessments.

The QuantaFlo™ PAD test delivers fast, accurate results in about five minutes at the point of care. In March of 2015, Semler Scientific received Food and Drug Administration (FDA) 510 (k) clearance for the next generation version of QuantaFlo™, which commercially launched in August of 2015.

The Company also has its WellChec™ service. WellChec™ provides turn-key assessment testing across the U.S. for an assortment of conditions. It provides turnkey solutions for administering important clinical tests, which can impact HCC classifications, CPT coding, HEDIS and Quality Measures. The Company launched its multi-test service platform, WellChec™ in April of 2015.

In October of 2016, Semler Scientific shifted its marketing emphasis for WellChec™ from direct contracts with health insurance plans under which the Company acted as the primary WellChec™ service provider to contracts to supply its software and equipment to vendors who employ medical professionals to do yearly wellness visits for health insurance plans.

Yesterday, Semler Scientific announced that it will report Q4 and full year 2017 financial results before the open of U.S. financial markets on Wednesday, February 28, 2018. Doug Murphy-Chutorian, M.D., Semler Scientific’s Chief Executive Officer, will host a conference call at 11 a.m. ET the same day.

Semler Scientific, Inc. (SMLR), closed Wednesday's trading session at $13.80, up 4.15%, on 28,855 volume with 87 trades. The average volume for the last 60 days is 20,261 and the stock's 52-week low/high is $2.77/$13.32.

chart

Integra Resources Corp. (IRRZF)

High Rising Stocks, Stockwolf, TradingView, Penny Stock Hub, Investing News Alerts, TheHotPennyStocks, Barchart, TheProspectorNews, and Dividend Investors reported on Integra Resources Corp. (IRRZF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

A development-stage company, Integra Resources Corp. engages in the acquisition, exploration and development of mineral properties in the Americas. The Company’s chief emphasis is advancement of its DeLamar Project. The Company previously went by the name Mag Copper Limited. It changed its name to Integra Resources Corp. in August of 2017. OTCQB-listed and incorporated in 1997, Integra Resources is based in Vancouver, British Columbia.

The Company’s management team consists of the former executive team from Integra Gold Corp. Integra Resources’ DeLamar Project comprises the neighboring DeLamar and Florida Mountain Gold and Silver Deposits in the heart of the historic Owyhee County mining district in southwestern Idaho.

This year, Integra Resources will begin a $10 million drill program at DeLamar. The 2018 exploration program will include aggressive drilling, metallurgical testing, geophysical surveys, and field sampling, mapping and prospecting. Furthermore, it will include a technological approach to targeting.

Previously, the DeLamar and Florida Mountain Project were operated by Kinross Gold Corporation. It produced gold and silver until 1998. At that time, low metal prices led Kinross Gold to place the project on care-and-maintenance.

The DeLamar Project consists of approximately 5,300 acres of patented and unpatented claims, and a further 4,100 acres of leased lands with roughly 1,575 historic drill holes and 145,940 meters of drilling outlined in historic databases.

In January, Integra Resources announced that it acquired a 100 percent interest in the Empire Claim Group for USD $1.6 million. The Empire Claim Group encompasses more than 95 percent of the past producing Florida Mountain gold-silver Project. Integra Resources’ newly acquired interest is free of all royalties and other kinds of financial encumbrances. With this agreement, Integra Resources acquired 36 patented mining claims totaling about 440 acres.

Florida Mountain hosts a significant drill database comprising greater than 1050 holes. These were mainly drilled by Kinross and Nerco to define open pitable oxide mineralization.

Last week, Integra Resources announced that it completed a maiden NI 43-101 resource estimate on the newly acquired Florida Mountain Gold and Silver Deposit. This Deposit is 8.5 km east of the Company’s DeLamar Deposit in southwestern Idaho. For the purposes of NI 43-101 reporting, Florida Mountain and DeLamar are now considered to be part of the global DeLamar Project. The basis of this is on the reasonable expectation that if put into production, and as in the past, the two deposits would likely share common infrastructure.

The maiden resource estimate at Florida Mountain is defined by 840-plus historical drill holes drilled to an average depth of 130 meters, incorporating greater than 108,000 meters of historic drilling.

This week, Integra Resources announced that it started drilling at the DeLamar Gold-Silver Project. Phase one of drilling has been increased 50 percent to 6,000 meters. This is to further define targets for Phase two of drilling, scheduled to commence this spring.

Phase one will include 18 reverse circulation (RC) drill holes. In excess of 20,000 meters of RC and diamond hole drilling is planned at the DeLamar and Florida Mountain Deposits this year.

Integra Resources Corp. (IRRZF), closed Wednesday's trading session at $0.6968, up 1.07%, on 19,500 volume with 11 trades. The average volume for the last 60 days is 7,359 and the stock's 52-week low/high is $0.05/$1.83.

chart

NaturalShrimp, Inc. (SHMP)

SmallCapVoice, Pennystockmania, ThePennyPicks, PennyPickGains, and WallstreetSurfers reported earlier on NaturalShrimp, Inc. (SHMP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, NaturalShrimp, Inc. is an international leader in aquaculture technology. The Company has developed and tested the first commercially-viable system for growing shrimp indoors. The system employs a proprietary technology to reliably produce healthy, naturally-grown shrimp weekly without the use of antibiotics or toxic chemicals. NaturalShrimp is based in Dallas, Texas.

NaturalShrimp’s production facility is outside of San Antonio, Texas. The Company’s European partner has built a production facility in Medina del Campo, Spain. Expansion plans include domestic and worldwide production facilities and distribution channels.

NaturalShrimp, Inc. owns 100 percent of NaturalShrimp Corporation, formed to operate in the United States and Canada, and 100 percent of NaturalShrimp Global, Inc., established to create International Joint Venture (JV) Partnerships.

NaturalShrimp has developed a technology to produce fresh, gourmet-grade shrimp dependably and economically in an indoor, re-circulating, saltwater facility. Its eco-friendly, bio-secure design does not depend on ocean water. It recreates the natural ocean environment allowing for high-density production, which can be replicated anywhere globally.

The NaturalShrimp Automated Monitoring and Control system utilizes individual tank monitors to automatically control the feeding, the oxygenation, and also the temperature of each of the facility tanks independently. In addition, a facility computer, running custom software, communicates with each of the controllers and performs additional data acquisition functions that can report back to a supervisory computer from anywhere in the world.

The computer automated water controls optimize the growing conditions for the shrimp as they mature to harvest size. This provides a disease-resistant production environment.

NaturalShrimp, along with its technology partner F&T Water Solutions, LLC, has teamed with Filtertech, Inc. on manufacturing the production equipment package to initially be installed at NaturalShrimp’s La Coste facility. The proprietary equipment package is the basis of the Company’s patented technology. The equipment covers NaturalShrimp’s base process of growing healthful, naturally grown shrimp without the use of chemicals and/or antibiotics.

In essence, NaturalShrimp’s production facilities will be the aquaculture industry’s first truly eco-friendly, sustainable way of cultivating shrimp in high density environments. The Company’s closed system production methods will produce fresh, gourmet grade shrimp without the use of antibiotics, pollutants, and other chemicals or without further depleting the globe’s oceans from overfishing.

Mr. Gerald Easterling, Mr. Bill G. Williams, and Mr. Tom Untermeyer founded NaturalShrimp in 2001. Mr. Williams serves as Chairman and Chief Executive Officer. Mr. Easterling serves as President. Mr. Untermeyer serves as Chief Technology Officer.

NaturalShrimp, Inc. (SHMP), closed Wednesday's trading session at $0.0319, up 8.87%, on 1,779,866 volume with 44 trades. The average volume for the last 60 days is 655,522 and the stock's 52-week low/high is $0.02/$1.00.

chart

OWC Pharmaceutical Research Corp. (OWCP)

CFN Media Group, Promotion Stock Secrets, and Cannabis Financial Network News reported previously on OWC Pharmaceutical Research Corp. (OWCP), and today we report on the Company, here at the QualityStocks Daily Newsletter.

OWC Pharmaceutical Research Corp. involves in the research and development (R&D) of cannabis-based medical products. It provides medical products for the treatment of diverse medical conditions and/or diseases. These include multiple myeloma, psoriasis, PTSD, and migraines; as well as delivery systems. One World Cannabis Ltd. is a wholly-owned subsidiary of OWC Pharmaceutical Research. OTCQB-listed, OWC Pharmaceutical Research has its headquarters in Petach Tikva, Israel.

The Company has entered into research and collaboration agreements with three of the leading research institutions in Israel. These include Sheba Academic Medical Center, one of the top academic hospitals in the Middle East.

These agreements serve as the underpinning for OWC’s clinical trials. They ensure that all of its studies have been, and will continue to be, founded on established research protocols of the U.S. Food and Drug Administration (FDA), Institutional Review Boards, and Independent Ethical Committees.

One World Cannabis’ Research Division centers on pursuing clinical trials evaluating the effectiveness of cannabinoids in the treatment of varied medical conditions. Its Consulting Division’s dedication is to helping governments and companies navigate complex worldwide cannabis regulatory frameworks. A medical cannabis R&D business, all of the Company’s research takes place at foremost Israeli hospitals and scientific institutions. They are led by internationally distinguished investigators.

OWC Pharmaceutical Research has completed the development of a proprietary, cannabinoid-enriched sublingual tablet for the administration of medical cannabis. The technology behind the tablet is protected. It provides for the ingestion of almost any dosage of medical cannabis with a sublingual delivery mechanism, where the compounds are absorbed directly into the patient's blood by way of oral epithelial tissue.

OWC Pharmaceutical Research has received the first ever Institutional Review Board (IRB) approval to conduct a safety study for a cannabis-based topical cream with greater than 3 percent THC. The Company is conducting a safety study (FDA Phase 1 equivalent) in one of the largest academic hospitals in Israel.

OWC has also completed the development of an orally disintegrating tablet, an important new delivery form. In addition, the Company’s topical cream for Psoriasis is ready for market.

This past December, OWC Pharmaceutical Research received a new permit from the Israel Medical Cannabis Agency (MCA) to go on with the safety study of the Company’s oral disintegrating tablet. The study protocol was to be submitted to the Institutional Review Board (IRB) at a foremost Israeli academic hospital. The study is scheduled to commence in Q2 2018.

The Cannabis Tablet provides a delivery modality that avoids all the disadvantages of smoking regular tobacco products. It has no significant smell, a fixed dosage, and is user-friendly.

Today, OWC Pharmaceutical Research announced the appointment of Dr. Oron Yacoby Zeevi as the Company’s Chief Scientific Officer (CSO). Dr. Yacoby Zeevi has over two decades of wide-ranging scientific experience with private and publicly listed companies in the biopharmaceutical industry. Dr. Yacoby Zeevi is the inventor of more than 50 issued patents and pending patents.

OWC Pharmaceutical Research Corp. (OWCP), closed Wednesday's trading session at $0.235, up 2.22%, on 781,737 volume with 166 trades. The average volume for the last 60 days is 432,202 and the stock's 52-week low/high is $0.20/$0.85. 

chart

The QualityStocks Company Corner

Choom Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF)

The QualityStocks Daily Newsletter would like to spotlight Choom Holdings Inc. (CHOOF).

Choom™ (CSE: CHOO) (OTCQB: CHOOF) (the "Company") is pleased to announce a non-brokered private placement for gross proceeds of up to $10,000,000, including a $7,000,000 lead order from Aurora Cannabis Inc.  The private placement will consist of up to 14,084,507 common shares at a price of $0.71 per share and is expected to close on June 18, 2018.

Choom Holdings Inc. (OTCQB: CHOOF) (CSE: CHOO) channels the laid-back spirit of Hawaii to the Okanagan region of British Columbia with a generous nod to the inspirational, yet unofficial, history of the 1970s “Choom Gang,” a group of buddies in Honolulu (including former President Barack Obama) who knew how to relax with “choom,” the local’s term for marijuana. Choom’s trademark slogans pivot off another unconventional phrase (“Say Hello to…”), bringing a heady dose of good times and good friends together as the company invites investors to “Say Hello to Choom™” as it lights up the adult recreational cannabis market in Canada.

Choom™ has been an ACMPR (Access to Cannabis for Medical Purposes Regulations) applicant since November 2013 in Vernon, B.C. The company’s first application has received security clearance and is now in the detailed review stage. They also recently announced their second late-stage ACMPR application, which is in its confirmation of readiness stage. Cannabis Compliance Inc. has been retained to help expedite Choom’s initial license applications to ensure the company’s readiness for legalization of recreational marijuana in Canada mid-summer 2018.

True to the company’s character, Choom™ is retrofitting two large facilities – No. 1 in Vernon, B.C., and No. 2 on Vancouver Island – to house its cannabis growing facilities. Phase 1 of the Vernon property will provide Choom™ with 6,800 square feet of growing space, capable of producing 660 kg/year of cannabis at an estimated revenue of $6.6 million, excluding oils. The company expects this facility to be completed by July 2018, the same month that Canada is expected to formally legalize recreational marijuana for adult use. A potential Phase 2, to be completed by the end of 2018, would add another 6,800 square feet for a total of 1,500 kg/year capacity, which would nearly double No. 1’s revenue. A Level 9 vault is also planned with a storage capacity of 15,000 kg. While the No. 2 facility on Vancouver Island is smaller – 4,500 square feet – its retrofit is also slated to be completed by July 2018. Plans include doubling this space as well, which would add about $9 million in annual revenue, excluding cannabis oils.

Choom™ announced its retail dispensary strategy with the intention of establishing market leadership in reaching the Canadian cannabis consumer. The partner program is already in the retail space design stage as the company seeks to build a chain of branded retail cannabis dispensaries in jurisdictions in Canada where recreational cannabis is legal. Choom™ Stores will have a cool, modern layout and design created to emit an authentic “Aloha” vibe. Choom™ is all about producing high-grade cultivars and curating them for a bigger audience.

A savvy, experienced management team includes Chris Bogart, president and CEO; John Oh, R.P.I.C., Operations Manager; Robert Bayrack, Master Grower, S.P.I.C.; and Adrian Robinson, Strategic Advisor. Bogart has over two decades of international experience in capital markets and was a co-founder of InMed Pharmaceuticals and Magnum Uranium. He has structured complex equity financing transactions in the U.S., Europe and Canada. Bogart is joined on the Board of Directors by Kevin Pull, Stephen Tong and John Oh.

While the medical marijuana industry is expected to double by 2021 to 500,000 registered users, the true highlight of the recreational cannabis represents the key cultural shift set to launch in Canada. With an estimated $4.9B to $8.7B retail market coming, now is the right time for a Recreation Brand like Choom™ to be involved in this growing industry. Establishing and maintaining Choom™ premium brand loyalty is a key factor in the company’s growth strategy. Get ready to “Say Hello” to opportunity, good times and good friends with Choom™.

Choom Holdings Inc. (CHOOF), closed the day's trading session at $1.02, up 39.00%, on 6,614,851 volume with 3,802 trades. The average volume for the last 60 days is 205,281 and the stock's 52-week low/high is $0.18/$0.8612.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a worldwide leader in enhancing the gastro-intestinal delivery of edible cannabinoid products. The company has its patented nutrient infusion technology called DehydraTECH™. This technology significantly improves the body’s ability to absorb cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, nicotine, drugs, supplements and other beneficial molecules. Lexaria Bioscience is headquartered in Kelowna, British Columbia.

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body’s gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria’s products and others on the market is the company’s disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the “unusual” taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria’s processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company’s patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria’s lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world’s most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed the day's trading session at $2.12, up 7.61%, on 402,513 volume with 805 trades. The average volume for the last 60 days is 251,362 and the stock's 52-week low/high is $0.27/$2.54.

Recent News

chart

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H)

The QualityStocks Daily Newsletter would like to spotlight PreveCeutical Medical Inc. (PRVCF).

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) continues working to shore up its share appeal while seeking remedies for a variety of physical ailments through its nature-centric research to help patients with type 2 diabetes and obesity, mild traumatic brain injury, cancer and pervasive pain.

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H), headquartered in Vancouver, British Columbia, Canada, is a health sciences company dedicated to researching and developing innovative options for preventive and curative therapies utilizing organic and Nature Identical™ products. The company is strategically staking out select positions in the medically acute areas of diabetes and obesity, pain management, neurological disorders and cancer.

PreveCeutical Medical Inc. had its beginnings in 2009 when Stephen Van Deventer, a seasoned businessman and venture capitalist, and Kimberly Van Deventer, a successful entrepreneur, met and formed a business partnership. The duo created Cornerstone Global Partners, a venture capital and business development company, and became involved in numerous ventures including building companies such as Aurora Cannabis Inc. Taking their interest in the health and wellness market further, the pair began researching how nature and science can work together to benefit health-conscious consumers. Coining and trademarking the word “PreveCeutical” – a combination of the words “preventive” and “pharmaceutical” – was a precursor to the company’s formation and incorporation in October 2015.

The company’s first product was developed in the Dominican Republic and is now marketed and distributed worldwide by PreveCeutical. It is a Caribbean Blue Scorpion venom product sold under the trade name CELLB9®. This product is an oral dilute solution infused with select peptides sourced exclusively from the blue scorpion (Rhopalurus princeps) found only in Caribbean nations. The active potentiated ingredients in CELLB9, which have been used in over 40 countries for over a decade, appear to support health at a deep, cellular level. PreveCeutical’s research team is using proprietary chemistry to generate Nature Identical™ peptides derived from natural compounds found in Caribbean Blue Scorpion venom with the goal of eventually treating, regulating and preventing cancer progression. Peptides are also being used to target an array of disease indications including metabolic disorders, pain management, cancers, cardiovascular and infectious diseases.

PreveCeutical is developing the first nose-to-brain delivery system of cannabinoids (CBDs) with a novel process that prepares insoluble drug-containing nano-micelles and successfully incorporating them into a proprietary sol-gels application, essentially creating a targeted drug delivery vehicle. Intended for use via a nasal spray, this unique formulation rapidly gels upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This novel application eliminates first pass metabolism (stomach, intestines, liver), potentially improving bioavailability and delivering extended time release formulations that may alleviate side effects of higher dosage therapeutics. This CBD-based patented formula is projected to be deployed in selected markets with licensed medical marijuana companies within 18 months.

PreveCeutical is working with four leading Australian research centers to develop a curative therapy for diabetes and obesity. This four-year program involves engineering a novel approach that selectively targets the gene that encodes for the protein PTP-1B, which is implicated and over-expressed in both type-2 diabetes and obesity. PreveCeutical’s gene-silencing technology would effectively “turn off” the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels, and prevent the body from storing excessive fat. Diabetes kills one person every six seconds, with more than $800 billion spent globally on the disease.

Another exciting joint venture, established with Sports 1 Marketing, will focus on the therapeutic potential in the peptides and proteins connected to the Caribbean Blue Scorpion venom to potentially treat mild brain injury concussions. Developing a therapeutic product geared towards athletes who suffer from concussions could help alleviate suffering experienced by those who are affected by head trauma.

PreveCeutical Medical’s science and research team is led by Dr. Harendra (Harry) Parekh, Ph.D., who is based at the University of Queensland’s (UQ) Pharmacy Australia Centre of Excellence (PACE), and Dr. Makarand Jawadekar, Ph.D., whose 28 years of R&D experience with Pfizer Inc., is applicable in his role as chief science officer. Research collaborators include Dr. Rakesh Veedu, an emerging expert internationally in the field of molecular medicine, and Professor Grant Ramm, who is currently head of a leading medical research institute located in Brisbane, Australia.

PreveCeutical Medical is partnering with leading industry experts and companies in its quest to be a leader in the preventive health sciences sector. Its Research and Development partnership with UniQuest, the main commercialization company for the University of Queensland, provides PreveCeutical with the rights to all intellectual property arising from projects created under the agreement. PreveCeutical Medical Inc.’s management team brings an extensive portfolio of research experience, product development, deep corporate strategy and capital markets leadership to the company’s core.

PreveCeutical Medical Inc. (PRVCF), closed the day's trading session at $0.0706, up 8.62%, on 82,300 volume with 5 trades. The average volume for the last 60 days is 16,915 and the stock's 52-week low/high is $0.002/$0.20.

Recent News

chart

Hammer Fiber Optic Holdings Corp. (OTCQB: HMMR)

The QualityStocks Daily Newsletter would like to spotlight Hammer Fiber Optic Holdings Corp. (HMMR).

Hammer Fiber Optic Holdings (OTCQB: HMMR) was featured in a news release from Emerging Markets Report highlighting HMMR’s technology, built on a hybrid architecture between fiber optic long haul infrastructure and high capacity wireless last mile innovation.

Hammer Fiber Optic Holdings Corp. (HMMR), with headquarters in New Jersey, is a telecommunications company investing in the future of wireless technology. The company’s holdings include Hammer Fiber Optic Investments, Ltd., D/B/A Hammer Fiber, an Internet Service Provider (ISP) that offers internet, voice, video and data services in New Jersey as well as carrier services in Philadelphia and New York. Hammer Fiber serves residential and small business markets with high-capacity broadband, voice and video through direct fiber as well as its wireless fiber platform – Hammer Wireless® AIR technology.

Hammer Fiber recently completed the initial development phase of its advanced LTE fixed wireless system, which was designed and built upon its successfully deployed wireless technology suite. The expansion allows Hammer Fiber to add ultra-high capacity cellular broadband applications to its product portfolio including wholesale services such as backhaul support for cellular network operators. Designed to complement Hammer Fiber’s core business of home residential service, the company expects this latest innovation to help position Hammer Fiber as a leader in future 5G technology. The company intends to leverage the Fixed LTE system in conjunction with its already deployed Fixed Wireless DOCSIS 3.1 system to deliver on one of its core promises, to deliver high capacity broadband to markets across the country at dramatically lower cost than traditional wireline methods, including fiber. Live field testing of the new system begins in early 2018 in the U.S. with service availability to follow later in the year.

Hammer Fiber has also expanded its IaaS (Infrastructure-as-a-Service) cloud services to include support for the cryptocurrency and blockchain industry. Interested companies will be able to host their products over Hammer Fiber’s robust and modern server infrastructure, fiber network architecture and data center presence in some of the most secure locations in the New York, New Jersey and Philadelphia regions. Hammer Fiber’s servers feature best-in-class computing power, designed to allow enterprise businesses to reap the benefits of utilizing a cloud-based system without the massive cost of establishing or maintaining a corporate data center.

“Distributed architecture infrastructure, such as those utilized by blockchain entities mining cryptocurrencies or other new vertical markets utilizing blockchain technology, are growing exponentially and we are poised to fulfill a critical but fundamental need of this explosive new industry,” said Mark Stogdill, CEO of Hammer Fiber. “The distributed ledger architectures that blockchains are built on require secure and robust data processing networks, highly scalable power generation and a reliable fiber optic backbone infrastructure linking up data centers worldwide for them to exist, and that is what we at Hammer Fiber do really well.”

Hammer Fiber seeks to achieve its vision by employing an extremely qualified group of business professionals with diverse backgrounds and successful track records from a variety of related industries. HMMR’s seasoned leadership team combines startup expertise with a consummate understanding of the regional competitive telecommunications landscape in sales, marketing, engineering, construction and business development.

Hammer Fiber Optic Holdings Corp. (HMMR), closed the day's trading session at $1.67, up 8.44%, on 579,442 volume with 631 trades. The average volume for the last 60 days is 36,760 and the stock's 52-week low/high is $0.882/$48.00.

Recent News

chart

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE).

Global Payout, Inc. (GOHE) (“Global”, the “Company”) is very pleased to announce that as part of the reverse triangular merger the Company is completing with MoneyTrac Technology, Inc. (“MTRAC”) announced publicly on June 5, 2018, MTRAC will be integrating its existing Executive Management Team into Global as part of MTRAC’s transition into the public entity.

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout’s fully configurable “banking-in-a-box” web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today’s banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout’s management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and “high-risk” market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and “high-risk” enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions.

Global Payout, Inc. (GOHE), closed the day's trading session at $0.0162, up 1.25%, on 5,299,532 volume with 147 trades. The average volume for the last 60 days is 8,513,271 and the stock's 52-week low/high is $0.0099/$0.16.

Recent News

chart

Lithium Chile Inc. (TSX.V: LITH) (OTCQB: LTMCF)

The QualityStocks Daily Newsletter would like to spotlight Lithium Chile Inc. (LTMCF).

Lithium Chile Inc. (TSX.V: LITH) (OTC: LTMCF) is pleased to announce that it has entered into a memorandum of understanding ("MOU") with Prosper One International Holdings Company Limited ("Prosper One"), a Hong Kong Stock Exchange listed company.

Lithium Chile Inc. (TSX.V: LITH) (OTCQB: LTMCF), headquartered in Canada, is advancing one of the largest lithium-rich exploration portfolios in Chile consisting of more than 148,000 hectares covering sections of 13 salars or mineral salt flats and one laguna complex. The company’s wholly owned premier properties include 66 square kilometers on the Salar de Atacama, Chile’s largest mineral salt flat which hosts the world’s highest concentration of lithium brine production and is currently the source of about 35 percent of the world’s lithium production. Lithium Chile also owns a significant copper/gold/silver property portfolio consisting of 28,184 hectares over six different properties.

Lithium Chile’s portfolio in the heart of Chile’s lithium-rich salars includes Salar de Coipasa, Salar de Helados, Salar de Atacama, Salar de Turi Salar de Ollague and Salar de Talar. Surface and near surface salt and brine sampling programs on all properties has been completed. To date, samples of high-grade, near-surface lithium brines at each of these projects are showing excellent chemistry of lithium to potassium and lithium to magnesium ratios. Good chemistry is important as it reduces your overall cost of production. Recent geophysical surveys including T.E.M have been completed on 5 of 6 priority targets and data collected to date has been extremely encouraging.

Lithium Chile has identified multiple high-priority brine target areas at its Atacama and Ollague lithium project areas. These areas display the same geophysical characteristics as the lithium-rich aquifers at Salar de Atacama, home to the world’s largest and highest-grade lithium brine producers. Spanning an area of 1,200 square miles, Salar de Atacama is the world’s third largest salt flat behind Salinas Grandes in Argentina and El Salar de Uyuni in neighboring Bolivia. Exploration drilling and resource definition drilling for these target areas are planned for 2018.

“We are delighted with the discovery of such impressive drill target areas at Atacama and Ollague. The results also follow the recent discovery of a 60km2 target area at another of our top Chilean projects – Helados – where we hope to drill in the second quarter of 2018,” stated President and CEO Steve Cochrane. “We have an aggressive multi-project drill program planned for this year, which includes all three of these exciting projects and we look forward to sharing drill results as they come through.”

Global demand for lithium-ion batteries is expected to surpass US$53 billion by 2024 as governments around the world aggressively seek to ban gas-powered vehicles and major automakers invest billions in new technology and electric vehicles powered by lithium-ion batteries. Chile’s mining-friendly jurisdiction offers Lithium Chile a clear, streamlined permitting process that significantly lowers the cost of lithium production to around $1,800/ton as compared to Australia’s $5,000/ton.

Lithium Chile is led by an experienced team with strong Chilean connections. Cochrane’s 36 years of investment industry experience have primarily been focused on the mining sector. During this time, he raised more than US$500 million for a variety of small cap public companies in various businesses and industry sectors including mining.

Terry Walker, P.Geol., vice president of exploration and chief geologist, is a highly experienced geologist. He has spent over 25 years in Chile’s mining industry and is well connected throughout the sector. Walker is co-founder of GeoServicios Piedra Dorada, an exploration and development services company focused on Latin America. He is a Qualified Person for the North American and Australian stock exchanges.

Lithium Chile is well funded and driven by a top-tier team with more than 100 years of combined experience in financing, mining exploration and development in the natural resources sector.

Lithium Chile Inc. (LTMCF), closed the day's trading session at $0.774, up 3.59%, on 118,734 volume with 102 trades. The average volume for the last 60 days is 14,666 and the stock's 52-week low/high is $0.6587/$0.9614.

Recent News

chart

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences Inc.’s (OTCQB: PBIO) ambitions to achieve listing on a major stock exchange this year have taken another major step forward as yet another group of debt holders have agreed to a debt-to-equity swap, this time amounting to $7.24 million, representing a strong message of investor support. The total amount of debt that has been converted to equity is now over $13.6 million, all in just the past four weeks (http://nnw.fm/y5V2d).

Pressure BioSciences Inc. (OTCQB: PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed the day's trading session at $3.50, up 0.57%, on 4,824 volume with 10 trades. The average volume for the last 60 days is 1,137 and the stock's 52-week low/high is $0.70/$8.50.

Recent News

chart

FANDOM SPORTS Media Corp. (CSE: FDM) (OTC: FDMSF) (FRANKFURT: TQ42)

The QualityStocks Daily Newsletter would like to spotlight FANDOM SPORTS Media Corp. (FDMSF).

FANDOM SPORTS Media Corp. (CSE: FDM) (OTC: FDMSF) (FRANKFURT: TQ42) is doing for sports fans today what the Circus Maximus did for ancient Romans. At this largest of Roman hippodromes (horse racing tracks), some 2,000 feet long and 600 feet wide, spectators were treated to captivating contests that typically featured 12 four-horse chariots racing for four miles as they traversed the Circus’ circumference seven times. Also today, NetworkNewsWire released a report on the company detailing how FDMSF recently launched an aggressive digital marketing campaign to launch its Android Sports App. To view the full article, visit: http://nnw.fm/bU33h.

FANDOM SPORTS Media Corp. (CSE: FDM) (OTC: FDMSF) (FRA: TQ42) taps into the primal, unfiltered passion of sports fans from around the world by providing an uncensored social media platform delivered through the FANDOM SPORTS mobile app. As an aggregator, curator and instigator of both company-created and user-generated content, the FANDOM SPORTS app is designed to entertain sports enthusiasts with real-time, interactive content on a mobile only app that offers bragging rights and real-life rewards. True sports addicts will appreciate an app that allows fans to pick a fight or create their own FanFights and rule over others as they trash talk their way to victory. The FANDOM SPORTS proprietary data centric “argument engine” measures and scores opinionated dialogue, as well as establishes consensus, giving fans and users the ability to dive deeper into one-of-a-kind cultural moments, cheer on favorite sports teams and slam dunk some sweet rewards.

Building on the company’s tag line – “Pick a Fight” – the FANDOM SPORTS app provides an always fresh, authentic rush of deeper-than-surface interactive content that resonates with the targeted age demographic of 18-34. Intense sports fans aren’t afraid of stepping up to the plate to engage other users by unleashing their opinions within the app’s structured debate resolution tool coined “FanFights.” Sports-loving fans can explore, gloat, vote, invite friends, create provocative FanFight topics and play to win while inside the FANDOM SPORTS app, which is currently available in the Apple App store and coming to the Google Play store imminently. The company’s self-learning algorithm predicts and collects user preferences while building relevant personalized FanFight channels, bringing the concept of competitive, in-your-face conversation to a whole new level of sports entertainment.

The FANDOM SPORTS app is free to play (F2P) with in-app purchase and subscription capabilities. The gaming aspect of the ecosystem is built on behavioral economics and delivers multiple revenue streams by maximizing average revenue per daily active user (ARPDAU) and user-generated content (UGC), with select placement of high-impact video and moment-based marketing as part of the brand-sponsored FanFights and in-app offers. The global platform enables applications (either FANDOM SPORTS created or 3rd party apps) to be operated in partnership with leading sports themed brands, leagues, and service providing companies within three verticals – live action, eSports, & fantasy – from around the world by supplying “interactive sports entertainment” to fans. The FANDOM SPORTS platform creates a bullet-proof snapshot of the app’s fan base through a Blockchain supported “PlayerCard” in tandem with the “Engagement Score”, which doubles as an invaluable acquisition and retention tool for its business operators. FANDOM SPORTS hosted transactions are placed on the distributed ledger, making them immutable and public to verified users interacting within the business ecosystem. Tracking this digital footprint provides extremely valuable metadata generated by users’ very dynamic behavior and sports passion.

FANDOM SPORTS’ Brand and Sponsorship partners are harnessing the affluent sports fans age 18-34 with integrated marketing content and service experience. The moments-based marketing integration will translate through FanCoin redemption, in exchange for items provided by programs established by FANDOM SPORTS and its clients. These programs are a key part of the business model and covers, as an example, the following partners; Sports Leagues, TelCo’s service offerings, and Content owners (i.e. FANDOM SPORTS provides new paying customers to the owners of pay-per-view platforms).

“Pick A Fight. Talk Trash. Get Rewarded.”

FANDOM SPORTS Media is an entertainment company that aggregates, curates and produces unique fan-focused content.

The FANDOM SPORTS App is the Company’s core product, which is the ultimate destination for unfiltered raw sports talk. The app allows passionate sports fans to unleash their primal sports passions, pick fights and earn rewards.

So download the app and bring your crew. Talking trash is better with friends. The more you invite, the more FanCoins you earn.

You may also visit the Company’s website at www.fandomsportsmedia.com or contact them directly at info@fandomsportsmedia.com.

DISCLAIMER:

The CSE has not reviewed and does not accept responsibility for the adequacy and accuracy of this information. This news release may contain forward-looking statements. These forward-looking statements do not guarantee future events or performance and should not be relied upon. Actual outcomes may differ materially due to any number of factors and uncertainties, many of which are beyond the Company’s control. Some of these risks and uncertainties may be described in the Company’s corporate filings (posted at www.sedar.com).

The Company has no intention or obligation to update or revise any forward-looking statements due to new information or events

FANDOM SPORTS Media Corp. (FDMSF), closed the day's trading session at $0.08331, even for the day. The average volume for the last 60 days is 7,745 and the stock's 52-week low/high is $0.0629/$0.3911.

Recent News

chart

Net Element (NASDAQ: NETE)

The QualityStocks Daily Newsletter would like to spotlight Net Element (NETE).

In the increasingly complex payments industry, companies have to provide new products and services to prove their relevance. Net Element, Inc. (NASDAQ: NETE) is providing novel payment solutions to the events industry while also expanding its existing services into Russia, carving a space in previously underserved niches.

Net Element (NETE), is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce, and mobile devices. Net Element operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest growing companies in North America on Deloitte’s 2017 Technology Fast 500 ™ and South Florida Business Journal’s 2016 fastest growing technology companies.

Net Element believes the future of global commerce is being revolutionized as consumers quickly migrate toward omni-channel shopping utilizing mobile devices, desktop, and online services. Net Element’s all-in-one payment solutions support and unify a whole range of applications through a single, robust platform, allowing global onboarding and support for multiple payment methods.

In a partnership with Bunker Capital, Net Element has also launched a new blockchain-focused business unit that will develop and deploy blockchain technology-based solutions. Net Element expects the new division to create a decentralized crypto-based ecosystem that will act as a framework for an unlimited number of value-added services, connecting merchants and consumers in a seamless, economically efficient transaction. This new business unit intends to also identify and invest in unique projects that decentralize and disrupt the payment processing industry by combining blockchain technology and real-world applications with talented development teams, strong fundamentals and addressable markets large in size.

“We believe that we’re at the dawn of a new evolution where additional digital payment methods are being introduced,” Net Element CEO Oleg Firer, says. “Introduction of our division focused on blockchain as part of the NASDAQ-listed entity will add transparency and compliance assurance to our investors as well as provide access to deploy value-added services to over 20 million electronic commerce clients that are currently part of Net Element’s growing network.”

Net Element clients are treated to customized solutions that provide the flexibility needed to keep up with customers. Among the services offered are mobile payment apps that accept payments anywhere, anytime; cloud-based solutions built to increase productivity and enhance revenue for clients and partners; marketing solutions that turn lookers into buyers; and business analytics that make it easy for clients to monitor business metrics, engage with customers and compare the competition. Its multi-channel platform combines e-commerce, offline, point-of-sale, comprehensive back office tools, mobile point-of-sale, credit scoring and customer interaction in one powerful platform-as-a-service technology.

Net Element owns and operates a global mobile payments and transactional processing provider, TOT Group, Inc., with the following subsidiaries:

  • Unified Payments – An award-winning, customized mobile billing and payments solution, recognized by Inc. Magazine as the No. 1 Fastest Growing Company in America in 2012.
  • Digital Provider – A leading provider of SMS messaging and mobile billing solutions.
  • Aptito – A next-generation, all-in-one, cloud-based restaurant management and point-of-sale payments platform using wireless technology.
  • Payonline – A fully integrated, processor agnostic electronic commerce platform.

Net Element is ranked No. 418 on Deloitte’s 2017 Technology Fast 500™ list of North America’s 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies. Net Element grew 190 percent. The company’s chief executive officer, Oleg Firer, credits the company’s progression to organic growth in its North America Transactions Segment, specifically the success of its Unified Payments brand, which focuses on value-added payment acceptance solutions for small to medium enterprises in the United States.

“The Deloitte 2017 North America Technology Fast 500 winners underscore the impact of technological innovation and world class customer service in driving growth, in a fiercely competitive environment,” said Sandra Shirai, vice chairman, Deloitte Consulting LLP and U.S. technology, media and telecommunications leader. “These companies are on the cutting edge, and are transforming the way we do business.”

Net Element’s suite of application performing interfaces (APIs) and connectors power commerce for businesses of all sizes through multi-channel platforms, all-in-one digital solutions, and end-to-end encryption of cardholder data utilizing tamper resistant hardware that ensures integrity and simplifies security.

Net Element’s corporate team is led by director and CEO Oleg Firer, who is responsible for the overall vision, strategy and execution of the company’s mission of powering global commerce. He is joined by CFO Jonathan New, CPA, and Steven Wolberg, who is the company’s chief legal officer and secretary. Each corporate officer brings a unique blend of leadership, vision, experience and creative energy to the company.

From mobile payments and value-added transactional innovations such as Digital Provider and Aptito to e-commerce and retail payment transaction processing brands like Payonline and United Payments, Net Element is transforming the online and mobile experience.

Net Element (NETE), closed the day's trading session at $7.77, off by 1.02%, on 83,128 volume with 396 trades. The average volume for the last 60 days is 453,991 and the stock's 52-week low/high is $2.556/$33.51.

Recent News

chart

Marijuana Company of America Inc. (MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA).

Recent U.S. government interest in ensuring industrial hemp supply signals a period of growth for the cannabinoid industry. Marijuana Company of America Inc. (OTC: MCOA) is contributing to this growth through new hemp cultivation projects in both Canada and the U.S., to support its hempSMART subsidiary.

Marijuana Company of America Inc. (MCOA) (the “Company”) are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a U.S. stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing exponentially and consequently the founders of MCOA have constructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can be used to produce products that are carbon neutral or even carbon negative. It is one of the longest, strongest natural fibers on earth, used as a building material that is free of mold, pesticide-resistant, and fire proof. Hemp has also been described as a “super food,” which provides additional business opportunities. No part of the plant is left unused and the Company’s overall strategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.

Marijuana Company of America Inc. (MCOA), closed the day's trading session at $0.0436, up 2.11%, on 7,729,948 volume with 466 trades. The average volume for the last 60 days is 5,670,459 and the stock's 52-week low/high is $0.0188/$0.0728.

Recent News

chart

QMC Quantum Minerals Corp. (TSX-V: QMC) (FSE: 3LQ) (OTC: QMCQF)

The QualityStocks Daily Newsletter would like to spotlight QMC Quantum Minerals Corp. (QMCQF).

QMC Quantum Minerals Corp., (TSX.V: QMC) (OTC: QMCQF) (FSE: 3LQ) ("QMC" or "the Company") announces it has signed a non-disclosure agreement ("NDA") with an Asian-based manufacturing company which will allow them to test the Company's lithium mineralization identified by recent channel sampling of the Irgon Pegmatite Dike to see if it meets end-use requirements of the manufacturer's customers.

QMC Quantum Minerals Corp. (TSX-V: QMC) (FSE: 3LQ) (OTC: QMCQF) is a British Columbia based company engaged in the business of acquisition, exploration and development of natural resource properties. QMC’s focus is on creating shareholder value through strategic acquisition and development of high quality lithium, silver, gold, nickel, copper and zinc prospects.

QMC’s current properties are in the Canadian province of Manitoba, one of Canada’s most productive, centrally located mining regions. These resources include the Irgon Lithium Mine project and two Volcanic Massive Sulphide (“VMS”) properties – the Rocky Lake and Rocky-Namew known collectively as the Namew Lake District Project – which contain base metal-rich mineral deposits. Excellent access and well-developed mining infrastructure to the company’s wholly-owned Irgon Lithium Mine Project offers significant value and ramps up the near-term production schedule, putting QMC in a position to take advantage of rising lithium prices.

The region’s historic resource estimate of lithium is well documented in a 1956 Assessment Report developed by a previous owner, Lithium Corporation of Canada Ltd. The project’s historical resource estimate of 1.2 million tons grading 1.51% lithium-oxide over a strike length of 365 meters and to a depth of 213 meters is being updated by QMC through a detailed channel sampling and subsequent drill program.

North Face Software Ltd. recently created an interactive 3-D model of the Irgon Dike utilizing all historical data derived from past drilling and underground work. The 3-D model clearly demonstrates that exploration and underground development has only taken place on the central portion of the dike, leaving significant potential to quickly increase tonnage.

The company’s latest assay results, obtained from 144 channel samples at QMC’s Irgon Lithium Mine Project, provided encouraging and positive results that compare favorably with the historic assays. QMC has received a drill permit from the Sustainable Development Office of the Manitoba government and is in the process of requesting and assessing bids from drilling contractors. The company plans to begin a 2,000-meter drill program to confirm the historic lithium oxide assay results documented in the historic 1953-54 drill program.

QMC’s experienced leadership team includes specialists in mineral exploration, geology, engineering, new business development, marketing and investor relations. The company’s team of qualified advisors includes consultant Bruce E. Goad, P.Geo., who has 40 years of experience in mineral exploration in Canada, Argentina, Asia and Africa. As a Qualified Person, Goad has worked on numerous deposit styles including rare element pegmatites, porphyry, banded iron formation (BIF) gold deposits, skarn, greisens,  and VMS. He has a wide and varied skill set which includes precious, base, industrial and rare metal projects with a sharp focus on gold exploration. Goad is the author of several scholarly publications on pegmatite granites of the southeastern Manitoba region.

The market for lithium has surged over the past three years with prices per metric ton tripling. The world’s rising demand for portable power can easily been seen in the electric vehicle and mobile device industries – both of which use lithium-based, renewable batteries as a power resource. QMC’s high potential prospects and experienced management team, both in geology and corporate finance, put QMC and its shareholders in an excellent position to take advantage of the lithium, precious and base metals markets.

QMC Quantum Minerals Corp. (QMCQF), closed the day's trading session at $0.398, off by 1.32%, on 130,113 volume with 57 trades. The average volume for the last 60 days is 126,997 and the stock's 52-week low/high is $0.0748/$1.46.

Recent News

chart

Consorteum Holdings, Inc. (CSRH)

The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH).

Software development and mobile solutions company Consorteum Holdings’ (OTC: CSRH) key product, its Universal Mobile Interface™ (“UMI”), offers a platform that was designed to assimilate any data onto mobile devices, regardless of the operating system. To view the full article, visit: http://nnw.fm/MPf7Q.

Consorteum Holdings, Inc. (CSRH) is a software development and mobile solutions company focused on the delivery of digital offerings to mobile devices. The company provides mobile offerings, delivery of mobile content, mobile payments solutions and products through a mix of direct offerings, partnerships, license agreements and joint venture arrangements. A multi-year transition from a transaction management company focused on transaction processing solutions and products for the payment processing and financial transaction markets to multiple business verticals deepens the company’s commitment to deliver innovating solutions to end users who are using smart handset devices in radical new ways.

Consorteum Holdings, utilizing its Universal Mobile Interface™ (“UMI”) solution, offers opportunities in numerous markets with its capacity to support fully regulated, regionally compliant financial and social transactions via web and mobile. The company’s UMI technology has the capacity to provide solutions in FinTech, data analytics, secure payment processing, compliance lead transaction management and various digital social event sectors. The UMI platform allows cross operating system development to support all mobile devices while addressing the complex and highly regulated needs of the mobile FinTech industry.

Led by the development team at Consorteum’s wholly owned subsidiary 359 Mobile Inc., the Company has created an end-to-end FinTech solution utilizing the company’s UMI technology platform. Current mobile application and transaction solutions are plagued by poor experiences. Because UMI’s technology platform is designed to work across innovative payment, experience and product solutions, 359 Mobile believes there are both direct and partnership opportunities for the 359 Mobile UMI solution.

Consorteum’s primary sales and marketing strategy is focused on enabling and delivering solutions to the global mobile FinTech market with an emphasis initially on mobile gaming. The trend towards increased mobile gambling supports the need for a mobile platform such as the UMI to meet existing and new compliance regulations for the online gambling industry. The online gambling market is projected to double to nearly $1 trillion by 2021, according to a study by Juniper Research, with the majority of growth in this sector attributed to mobile devices. Consorteum’s management team believes there are fresh opportunities in this sector such as Mobile Marketing Services providing one-to-one marketing experiences for consumers; offering real-time services to Mobile Sports Book operators; and providing fixed odds betting solutions as well as social-based transactional solutions.

Consorteum’s management team includes Chairman and CEO Craig A. Fielding, a co-founder of the company with extensive experience in technology, programming and large system building; and Chief Operating Officer Patrick Shuster, who has over 25 years of business experience in sales, engineering, operations and marketing for the telecommunications industry. They are joined by John Osborne, SVP of Technology of ThreeFiftyNine Inc., an innovator in embedded systems hardware and software design; Patrick Doran, SVP of business development and marketing with over 30 years of diversified experience in major corporations as well as early stage companies; and Glenn Charlesworth, VP of Accounting, a seasoned executive with a solid track record in financial reporting, strategic planning, general management and operations, finance, start-up situations, and cash flow challenged operations.

Consorteum Holdings is committed to bridging the mobile divide by providing mobile connectivity, secure transactional processing and social connectivity solutions for both cloud and hosted based offerings in multiple business sectors.

Consorteum Holdings, Inc. (CSRH), closed the day's trading session at $0.0021, off by 8.70%, on 7,084,575 volume with 32 trades. The average volume for the last 60 days is 11,256,136 and the stock's 52-week low/high is $0.0005/$0.0085.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.